![]() In recent years, it has been found that PBMCs play an important role in the occurrence and development of NSCLC. These different cytokines have more or less inhibitory effect on tumor. PBMCs can secrete many kinds of cytokines, including interleukin and tumor necrosis factor (TNF). In patients with abnormal immune system or immunodeficiency, the incidence of tumor will be greatly increased, and the speed of canceration will be significantly accelerated. The immune system can remove mutated cells from the body and early tumor cells. Peripheral blood mononuclear cells, including lymphocytes and monocytes, are important cellular components of the body’s immune response. So, GSDMD and CASP1/4/5 play a key role in the occurrence of pyroptosis. In the non-classical pathway of pyroptosis, lipopolysaccharides (LPS) directly binds to activate Caspase-4/5, and Caspase-4/5 induces pyroptosis by cutting GSDMD. The N-terminal of gasdermin-D (GSDMD) leads to the opening of cell membrane pores, which leads to pyroptosis. In the classical pathway of cell death, under the stimulation of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), pattern recognition receptors (PRRs) such as NLR pyrin domain containing 3 (NLRP3), NLR containing a caspase recruitment domain 4 (NLRC4) and absent in melanoma 2 (AIM2) combine with the adapter protein ASC (apoptosis-associated speck-like protein containing a CARD) and Caspase-1 to form various inflammatory bodies to cleave GSDMD. According to the mechanism, pyroptosis can be divided into Caspase-1-dependent classical inflammatory body pathway and Caspase-4/-5-dependent non-classical inflammatory body pathway. In 2018, Nomenclature Committee on Cell Death (NCCD) defined it as regulated cell death with plasma membrane perforation formed by members of the Gasdermin protein family after inflammatory cysteinyl aspartate specific proteinase (caspase) activation. Pyroptosis is a mode of cell regulatory death accompanied by inflammatory response. As a newly discovered form of programmed cell death, pyroptosis may provide a new idea for the treatment and diagnosis of lung cancer. In the past few decades, targeted therapy and immunotherapy have become the focus of research on how to cure lung cancer. NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In 2020, there were more than 2 million new cases of lung cancer worldwide, and about 1.8 million people died of lung cancer. Lung cancer has a high incidence in the world and is one of the most malignant tumors. The early enhanced pyroptosis-related gene expression may be potential molecular markers for early diagnosis of non-small cell lung cancer. GSDMD, CASP1, CASP4 and CASP5 gene expression are highly increased in PBMCs of non-small cell lung cancer patients and their expression are closely related to the clinical characteristics of patients. ResultsĬompared with the control group, the GSDMD, CASP4 and CASP5 expression in PBMCs of lung cancer patients was significantly higher(P 0.05), 0.701(P < 0.05) and 0.628(P < 0.05), the sensitivity values were 84.5%, 67.6% 43.7%, and 84.3% the specificity values were 42%, 52%, 84% and 64%, respectively. The GSDMD, CASP1, CASP4, CASP5 expression and their relationship with the clinical characteristics of the patients were analyzed. The GSDMD, CASP1, CASP4 and CASP5 expression in peripheral blood mononuclear cells of the two groups were detected by real-time fluorescence quantitative PCR. ![]() Methodsħ1 non-small cell lung cancer patients were selected as the study group and 50 healthy individuals as the control group. To investigate the GSDMD, CASP1, CASP4 and CASP5 expression in peripheral blood mononuclear cells of non-small cell lung cancer patients and analyze their clinical significance.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |